A Phase 2 interventional study of fludarabine and treosulfan in Acute Myeloid Leukemia, sponsored by Institut Paoli-Calmettes. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by Institut Paoli-Calmettes · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies testing fludarabine in Leukemia, Myeloid, Acute — 34 open to participants now, 49 under way, 4 of them phase 3. fludarabine · Leukemia, Myeloid, Acute.
Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, this one is the 53rd largest by planned enrollment of the 188 interventional ones that give a count, is one of 10 that started in 2026, is one of 96 in phase 2, reaches primary completion later than 43 of the 48 other live ones, and was the 183rd registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →34 of the 191 studies testing fludarabine in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages 2–75
Roswell Park Cancer Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 127 · Phase 3 13 · Phase 4 3
First in 1996; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 77 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 47 across the 188 interventional studies. Of the 129 that completed or were terminated, 75 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 191 have an industry lead sponsor. The 10 most frequent:
Institut Paoli-Calmettes is the lead sponsor of 172 studies on the registry; 50 are open to participants now.
19 studies in Leukemia, Myeloid, Acute by Institut Paoli-Calmettes: 2 open now, 4 under way, none of them phase 3. Of 9 finished, 0 (0%) have results posted.
Among the 19 studies in Leukemia, Myeloid, Acute by Institut Paoli-Calmettes, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 2, and was the 19th registered.
Institut Paoli-Calmettes’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
14 of the studies testing fludarabine in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03121014University of Illinois at ChicagoStudy of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes | 2026-11 |
| NCT02143830Children's Hospital Medical Center, CincinnatiHSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | 2026-12 |
| NCT04644016Memorial Sloan Kettering Cancer CenterCord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders | 2026-12-20 |
| NCT04375631Fred Hutchinson Cancer CenterCLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia | 2027-02-28 |
| NCT04872595Memorial Sloan Kettering Cancer CenterA Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, from their registry updates:
Among Institut Paoli-Calmettes’s 19 in Leukemia, Myeloid, Acute:
This tab as a report to print or save as PDF → With an account.
Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) predominantly affect older adults, and their incidence continues to rise with advanced age. For many patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option capable of providing long-term disease control through the graft-versus-leukemia (GVL) effect. Historically, however, allo-HSCT was rarely offered to patients older than 50 years because of the high morbidity and mortality associated with myeloablative conditioning regimens and limited supportive care strategies. Over the past two decades, advances in reduced-intensity conditioning (RIC), infection prophylaxis, and donor availability have profoundly transformed the landscape, allowing increasing numbers of older patients to access transplantation.
Multiple studies have demonstrated that allo-HSCT confers a survival benefit in older AML patients in complete remission compared with consolidation chemotherapy alone.
The intensity of conditioning profoundly influences both relapse risk and non-relapse mortality (NRM). myeloablative conditioning (NMAC) regimens are attractive for older adults due to their low toxicity but rely solely on the immunologic GVL effect and thus carry a higher relapse risk. Reduced-intensity conditioning (RIC) regimens, incorporating intermediate-dose alkylating agents such as busulfan, melphalan, or thiotepa, offer stronger anti-leukemic effect but at the cost of greater toxicity.
These observations underscore the central question: can a conditioning regimen combine strong anti-leukemic potency with the low toxicity required for older patients undergoing Haplo-SCT? The main objective is to evaluate the efficacy of FT-RIC regimen before Haplo-SCT for older and/or frail patients diagnosed with AML, who are not eligible for a myeloablative conditioning (MAC) regimen.
To achieve this objective, the investigators will assess Progression Free Survival (PFS) defined as the time from allo-HSCT to AML relapse or death.
This is a Multicenter trial, single arm prospective of phase II. Once the conditioning has been administered and the transplant performed, the patient will receive standard routine follow-up care, with the addition of questionnaires, and for patients followed at the Institut Paoli Calmettes only, blood samples will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After screening and inclusion, patients will be given a RIC regimen based on the market-approved association of fludarabine and treosulfan (FT-RIC): * Fludarabine (concentrate for solution for injection/infusion) is a marketed purine analogue and antineoplastic agent. * Treosulfan (powder for solution for infusion) is a marketed alkylating medication
Drug: fludarabine and treosulfan
Drug pages: FludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TreosulfanStudies of TreosulfanTreosulfan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
As per standard practices, patients will be hospitalized during the treatment period. The treatment is administered by the nurses of the department under the responsibility of the investigator.Fludarabine (30 mg/m²/day from day-6 to day-2), iv andTreosulfan (10 g/m²/day from day-4 to day-2), iv
The main objective is to evaluate the efficacy of FT-RIC regimen before Haplo-SCT for older and/or frail patients diagnosed with AML, who are not eligible for a MAC regimen.
Progression Free Survival (PFS) defined as the time from allo-HSCT to AML relapse or death
Time frame: through study completion an average of 4 years
To evaluate adverse events related to the FT combination according to CTCAE V6.0
Conditioning related toxicity according to CTCAE V.6.0
Time frame: through study completion an average of 4 years
To evaluate engraftment after FT-RIC
rate of graft failure
Time frame: through study completion an average of 4 years
To evaluated hematological recovery after FT-RIC
Cumulative incidence of neutrophil and platelet recovery
Time frame: after hematological recovery
to evaluate incidence of both acute and chronic GVHD after FT-RIC
Cumulative incidence of acute GVHD and Cumulative incidence of chronic GVHD
Time frame: through study completion an average of 4 years
To evaluate survival, non-relapse mortality and cause of death after FT-RIC
Probability of Overall Survival and Probability of GVHD
Time frame: through study completion an average of 4 years
To evaluate the immunosuppressive therapy duration after FT-RIC
Prevalence of immunosuppressive therapy (IST) and GVHD at 3, 6, 9, 12 months
Time frame: through study completion an average of 4 years
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2030, 48 months later.
Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 48 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fludarabine · Treosulfan